Gallacher Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Gallacher Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-34,307	Closed	-$801K	–	321
2025 Q4	$801K	Sell	34,307 -134	-0.4%	-$2.98K	0.31%	80
2025 Q3	$678K	Buy	34,441 +18,960	+122%	+$390K	0.27%	108
2025 Q2	$336K	Sell	15,481 -742	-5%	-$17.5K	0.16%	188
2025 Q1	$393K	Buy	+16,223	New	+$365K	0.19%	154
2024 Q3	–	Sell	-18,564	Closed	-$288K	–	289
2024 Q2	$288K	Buy	+18,564	New	+$289K	0.15%	189
2024 Q1	–	Sell	-14,561	Closed	-$245K	–	273
2023 Q4	$245K	Sell	14,561 -3,076	-17%	-$42K	0.14%	208
2023 Q3	$206K	Buy	+17,637	New	+$236K	0.13%	218

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Gallacher Capital Management's CPRX Position: Q1 2026 in Review

Gallacher Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q1 2026, closing a stake of 34,307 shares — an estimated $801K sold.

Gallacher Capital Management first reported a position in CPRX in Q3 2023 and held it in 7 quarters. The position peaked at $801K in Q4 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Gallacher Capital Management reported no remaining Catalyst Pharmaceutical position as of Q1 2026 after selling out during the quarter.
Gallacher Capital Management sold 34,307 Catalyst Pharmaceutical shares in Q1 2026, an estimated $801K.
Gallacher Capital Management first reported a position in Catalyst Pharmaceutical in Q3 2023 and held it in 7 quarters.
Gallacher Capital Management's Catalyst Pharmaceutical position peaked at $801K in Q4 2025.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Gallacher Capital Management's 13F filing for Q1 2026, filed 6 May 2026.